Irf4 Related Immune Disorder Cn380025
An immune system disorder linked to gene changes that can cause recurrent infections and immune dysfunction. Management focuses on infection prevention and immune support.
Key facts at a glance
- ICD-10
- R69
- ICD-11
- MA00.0
- Body system
- immunologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Immunodeficiency with recurrent infections
Recurrent respiratory tract infections
Autoimmune manifestations
Generalized symptoms
(immunologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Specific antibody deficiency
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Immunoglobulin Replacement Therapy
Regular immunoglobulin G replacement to address antibody deficiency in IRF4-related immune disorder. Helps prevent recurrent bacterial infections and may reduce autoimmune complications.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Infection Prophylaxis Regimen
Targeted antimicrobial prophylaxis based on documented infections and immune profile. May include antibiotics for encapsulated bacteria, antivirals, and antifungals as indicated by clinical presentation.
Additional treatment options
Autoimmune Complication Management
Treatment of autoimmune manifestations with corticosteroids or steroid-sparing immunosuppressants when they occur. Requires careful balance between controlling autoimmunity and maintaining immune function against infections.
medicationComprehensive Immunologic Assessment
Regular evaluation of lymphocyte subsets, immunoglobulin levels, and specific antibody responses to guide treatment decisions. Includes monitoring for autoimmune markers and inflammatory complications.
monitoringInfection Prevention and Environmental Control
Implementation of strategies to reduce exposure to infectious agents including meticulous hand hygiene, food safety measures, and avoidance of known infection exposures. Patient and family education on early infection recognition.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Irf4 Related Immune Disorder Cn380025?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Irf4 Related Immune Disorder Cn380025. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy